top of page

Spravato Esketamine for Depression

Updated: Dec 18, 2023

Spravato® (esketamine) is an FDA-approved medication specifically designed to treat depression for people who have not responded to other treatments. Approved by the U.S. Food and Drug Administration (FDA) in 2019 as a nasal spray for treatment-resistant depression, Spravato® offers a new option for patients who have not found relief with other treatments.

Spravato® works by acting on a pathway in the brain that affects glutamate, the most abundant neurotransmitter in the brain, helping to regulate mood and emotions. It is administered as a nasal spray and is typically used in combination with an oral antidepressant under the supervision of a healthcare professional at our Gilbert, Arizona location. Patients are closely monitored for at least two hours after administration.

While Spravato® has shown effectiveness in clinical trials for treating depression, it is important to note that it may have potential side effects, including dizziness, dissociation, and sedation. Additionally, it carries a risk of abuse and dependence, which requires patients to be enrolled in a Risk Evaluation and Mitigation Strategy (REMS) program to ensure safe use.

At Lighthouse Psychiatry, we offer both Spravato® and Ketamine infusion as treatment options for patients with treatment-resistant depression. If you or a loved one are struggling with depression, our team is dedicated to helping you determine the best approach to improve your mood and overall brain health.

Contact us today for assistance.

35 views0 comments


bottom of page